Improving quality of life in multiple sclerosis

Canbex Therapeutics is dedicated to treating spasticity in multiple sclerosis (MS) and other disorders. Spasticity is a debilitating and painful symptom that consists of involuntary spasms and stiffness of limbs and torso. The goal of the Canbex lead programme is to improve the lives of people with this serious and incurable disorder, and set a new standard in the treatment of spasticity.

The company’s lead compound, VSN16R, is currently in a Phase II study to determine its efficacy in relieving spasticity in people with MS. VSN16R was shown to be safe and well tolerated in a Phase I human safety trial in healthy volunteers that was completed in 2014.

In February 2015, Canbex entered into an agreement with Ipsen SA, a leading global specialty pharmaceutical firm with expertise in spasticity and a commitment to providing better treatments for this important and poorly served medical need. For further information, please click here

Canbex is a spin-out of University College London, which remains a major shareholder along with the Wellcome Trust; MS Ventures, the corporate venture arm of Merck KGaA; and Esperante Ventures. The company has also received grant funding from the UK Technology Strategy Board. Canbex is especially grateful for early support provided by "Fast Forward", the drug development arm of the US National Multiple Sclerosis Society, that was pivotal in progressing from laboratory to clinic.

Our goal is to improve the quality of life for people with multiple sclerosis through better treatment of spasticity.